Dr. Helen Sabzevari was the Senior Vice President of Immuno-Oncology at the pharmaceutical company EMD-Serono. Sabzevari majored in immunology and immunobiology before going on to do a PhD in immunology, during which she became fascinated by the idea of activating the immune system against cancer. As a result, she went on to do her first postdoctorate in the field of cancer immunotherapy.

Dr. Helen Sabzevari is currently the Co founder and CSO at Compass Therapeutics. She is also the Co-Founder and Chief Scientific Officer of Compass Therapeutics LLC in Cambridge Massachusetts leading the company in the area of ImmunoOncology and Autoimmune diseases.

Dr. Sabzevari is internationally recognized for her work in the field of ImmunoOncology. Her contributions in the field of tumor immunology earned her the National Institutes of Health (NIH) merit award for major contribution to the field of cancer immunotherapy. She has been the Recipient of Mass High Tech’s Women to Watch Award and the PharmaVOICE 100 Award in 2013.

Prior to joining Merck Serono, she served as Head of the Molecular Immunology Group at the Laboratory of Tumor Immunology and Biology at the US National Cancer Institute (LTIB-NCI), where she led a large translational research program with the goals of design, development and delivery of novel vaccines and immunotherapies for a range of human cancers.

Dr. Sabzevari received her doctorate degree in cell and molecular immunology and completed her postdoctoral work at the department of immunology at the Scripps Research Institute working on various immunotherapeutic modalities in the treatment of cancer and autoimmune diseases.